Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Projects from Chia Tai and Kestrel enter phase 1, along with a bispecific Kelun ADC.
Circle Pharma and Verismo feature in coveted sessions.
KITE-753 is to enter pivotal development – head-to-head against Yescarta.
The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
Talapro-3 could help move Talzenna into earlier prostate cancer.
